Moritz Hillgenberg PhD MBA is our German anchor. He works out of his Berlin office and has been collaborating with us since the early years of groupH. He specializes in opportunity assessments and forecasting for early to mid-stage assets.

After earning a PhD in Molecular Biology from Humboldt-University Berlin for pioneering research on virus-based gene transfer vectors, Moritz started his early industry career in R&D at HepaVec AG, one of the first German gene therapy companies. He then headed the R&D activities of Custos Biotech GmbH, before moving to Berlin-based BDD/CCDRD Group, where he was responsible for planning and coordination of drug development projects in endocrinology, inflammation, and sleep disorders. An MBA from the IMB in Berlin then drove him into more commercial and operational roles as the COO of two affiliates of the group, before he started his consulting career in 2007.

Over the last 15 years, Moritz has worked on numerous consulting projects for preclinical, clinical, or market stage companies in US, EU, and Asia. Over time, he has accessed market opportunities for a large variety of innovative drug products across a broad spectrum of therapy areas, including oncology, autoimmune, CV, metabolic, infection, and rare diseases. He has developed deep expertise to help clients better understand their target market, maximise the value of their asset and take the right strategic decisions for development, partnering or funding. Besides that, Moritz is also working on new approaches to refine and further evolve commercial assessment processes with the help of innovative tools.

Outside work, Moritz loves to travel and explore the world’s diverse nature, cultures, and culinary traditions, and to discover unique local ingredients and specialties to grow his ‘global hidden gem recipe collection’.